Sponsored by
The CUSP9 protocol is an experimental treatment approach for recurrent glioblastoma that combines 9 repurposed drugs with low-dose continuous temozolomide (TMZ). While early studies showed the protocol can be safely administered under careful monitoring, researchers recently tested all subset combinations of the 9 drugs, in combination with TMZ, on two clonal cultures of glioma-initiating cells from patient samples. Results showed that several subset combinations produced equivalent effects to the full protocol. This study highlights the importance and feasibility of personalized treatment approaches based on functional testing. We are following research in this area closely!